VSTM

Over the past six months, Verastem's stock (VSTM) has shown significant momentum, posting a 37% return and gaining approximately 105% since June 30, 2026. Key events include exceptional commercial performance of AVMAPKI FAKZYNJA CO-PACK, with Q2 2026 total revenue reaching $40.1 million and net product revenue of $25.1 million, driven by new patient starts and increased prescription refills. The company also made significant clinical pipeline advancements, announcing positive updated results from the Phase 1b/2a RAMP 205 trial in June 2026. An upcoming data presentation for the phase 1/2 TARGET-D 101 data readout for KRAS G12D inhibitor VS-7375 is scheduled for October 14, 2026. Analyst sentiment remains generally positive, with an average 'Moderate Buy' rating and an average target price of $13.83, despite some target price adjustments. Verastem beat quarterly expectations, reporting a smaller loss per share and higher revenue than anticipated, and announced inducement grants on October 5, 2026.